These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 38522181)

  • 21. Impact of tissue-agnostic approvals for patients with sarcoma.
    Pestana RC; Beal JR; Parkes A; Hamerschlak N; Subbiah V
    Trends Cancer; 2022 Feb; 8(2):135-144. PubMed ID: 34887213
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tissue-agnostic drug approvals: how does this apply to patients with breast cancer?
    Weis LN; Tolaney SM; Barrios CH; Barroso-Sousa R
    NPJ Breast Cancer; 2021 Sep; 7(1):120. PubMed ID: 34518552
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evolution of the Targeted Therapy Landscape for Cholangiocarcinoma: Is Cholangiocarcinoma the 'NSCLC' of GI Oncology?
    Gupta A; Kurzrock R; Adashek JJ
    Cancers (Basel); 2023 Mar; 15(5):. PubMed ID: 36900367
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The application of target-based tissue-agnostic therapy in the treatment of lung cancer].
    Peták I
    Magy Onkol; 2020 Sep; 64(3):206-215. PubMed ID: 32966351
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of immunotherapy in patients with oncogene-driven non-small-cell lung cancer: a systematic review and meta-analysis.
    Chen J; Lu W; Chen M; Cai Z; Zhan P; Liu X; Zhu S; Ye M; Lv T; Lv J; Song Y; Wang D
    Ther Adv Med Oncol; 2024; 16():17588359231225036. PubMed ID: 38420602
    [TBL] [Abstract][Full Text] [Related]  

  • 26. NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types.
    Rolfo C; Drilon A; Hong D; McCoach C; Dowlati A; Lin JJ; Russo A; Schram AM; Liu SV; Nieva JJ; Nguyen T; Eshaghian S; Morse M; Gettinger S; Mobayed M; Goldberg S; Araujo-Mino E; Vidula N; Bardia A; Subramanian J; Sashital D; Stinchcombe T; Kiedrowski L; Price K; Gandara DR
    Br J Cancer; 2022 Feb; 126(3):514-520. PubMed ID: 34480094
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Site-agnostic biomarker-guided oncology drug development.
    Jørgensen JT
    Expert Rev Mol Diagn; 2020 Jun; 20(6):583-592. PubMed ID: 31813299
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hallmarks of RET and Co-occuring Genomic Alterations in
    Adashek JJ; Desai AP; Andreev-Drakhlin AY; Roszik J; Cote GJ; Subbiah V
    Mol Cancer Ther; 2021 Oct; 20(10):1769-1776. PubMed ID: 34493590
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rare cancer, rare alteration: the case of NTRK fusions in biliary tract cancers.
    Boilève A; Verlingue L; Hollebecque A; Boige V; Ducreux M; Malka D
    Expert Opin Investig Drugs; 2021 Apr; 30(4):401-409. PubMed ID: 33641556
    [No Abstract]   [Full Text] [Related]  

  • 30. Precision medicine becomes reality-tumor type-agnostic therapy.
    Yan L; Zhang W
    Cancer Commun (Lond); 2018 Mar; 38(1):6. PubMed ID: 29764494
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MSI-High RAS-BRAF wild-type colorectal adenocarcinomas with MLH1 loss have a high frequency of targetable oncogenic gene fusions whose diagnoses are feasible using methods easy-to-implement in pathology laboratories.
    Bocciarelli C; Caumont C; Samaison L; Cariou M; Aline-Fardin A; Doucet L; Roudié J; Terris B; Merlio JP; Marcorelles P; Cappellen D; Uguen A
    Hum Pathol; 2021 Aug; 114():99-109. PubMed ID: 34019865
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring
    Odogwu L; Mathieu L; Blumenthal G; Larkins E; Goldberg KB; Griffin N; Bijwaard K; Lee EY; Philip R; Jiang X; Rodriguez L; McKee AE; Keegan P; Pazdur R
    Oncologist; 2018 Jun; 23(6):740-745. PubMed ID: 29438093
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Histology-agnostic tumor treatment - a farewell to tumor entities?].
    Kerle I; Heining C
    Dtsch Med Wochenschr; 2023 Sep; 148(18):1174-1181. PubMed ID: 37657455
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Histology-agnostic drug development - considering issues beyond the tissue.
    Pestana RC; Sen S; Hobbs BP; Hong DS
    Nat Rev Clin Oncol; 2020 Sep; 17(9):555-568. PubMed ID: 32528101
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Emerging Tumor-Agnostic Molecular Targets.
    Bhamidipati D; Schram AM
    Mol Cancer Ther; 2024 Nov; 23(11):1544-1554. PubMed ID: 39279103
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Profiling of gene fusion involving targetable genes in Chinese gastric cancer.
    Liu ZH; Zhu BW; Shi M; Qu YR; He XJ; Yuan HL; Ma J; Li W; Zhao DD; Liu ZC; Wang BM; Wang CY; Tao HQ; Ma TH
    World J Gastrointest Oncol; 2022 Aug; 14(8):1528-1539. PubMed ID: 36160735
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination Therapy With MDM2 and MEK Inhibitors Is Effective in Patient-Derived Models of Lung Adenocarcinoma With Concurrent Oncogenic Drivers and MDM2 Amplification.
    Elkrief A; Odintsov I; Markov V; Caeser R; Sobczuk P; Tischfield SE; Bhanot U; Vanderbilt CM; Cheng EH; Drilon A; Riely GJ; Lockwood WW; de Stanchina E; Tirunagaru VG; Doebele RC; Quintanal-Villalonga Á; Rudin CM; Somwar R; Ladanyi M
    J Thorac Oncol; 2023 Sep; 18(9):1165-1183. PubMed ID: 37182602
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emergence of
    Subramanian J; Katta A; Masood A; Vudem DR; Kancha RK
    Oncologist; 2019 Dec; 24(12):e1303-e1314. PubMed ID: 31292270
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion.
    Chakravarty D; Johnson A; Sklar J; Lindeman NI; Moore K; Ganesan S; Lovly CM; Perlmutter J; Gray SW; Hwang J; Lieu C; André F; Azad N; Borad M; Tafe L; Messersmith H; Robson M; Meric-Bernstam F
    J Clin Oncol; 2022 Apr; 40(11):1231-1258. PubMed ID: 35175857
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.
    Wen S; Dai L; Wang L; Wang W; Wu D; Wang K; He Z; Wang A; Chen H; Zhang P; Dong X; Dong YA; Wang K; Yao M; Wang M
    Oncologist; 2019 Nov; 24(11):e1070-e1081. PubMed ID: 30902917
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.